Valuation: Elutia Inc.

Market Cap 41.91M 36.75M 33.88M 31.71M 59.47M 3.95B 60.7M 407M 158M 1.95B 157M 154M 6.78B P/E 2026 *
-1.58x
P/E 2027 * -1.82x
Enterprise Value 41.91M 36.75M 33.88M 31.71M 59.47M 3.95B 60.7M 407M 158M 1.95B 157M 154M 6.78B EV / Sales 2026 *
3.49x
EV / Sales 2027 * 3.2x
Free-Float
85.26%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week-6.37%
Current month-19.28%
1 month-17.87%
3 months-12.50%
6 months+72.27%
Current year+35.17%
1 week 0.93
Extreme 0.9322
1.07
1 month 0.93
Extreme 0.93
1.18
Current year 0.6
Extreme 0.6019
1.38
1 year 0.5
Extreme 0.5
2.64
3 years 0.5
Extreme 0.5
5.24
5 years 0.5
Extreme 0.5
11.1
10 years 0.5
Extreme 0.5
18.2
Manager TitleAgeSince
Chief Operating Officer 52 -
Chief Executive Officer 54 2022-06-20
Director of Finance/CFO 58 2020-09-27
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 54 2015-10-31
Director/Board Member 70 2020-08-31
Date Insider Type Main position Quantity % Market Cap.
06-20Fiscal year

Founder

53,010 0.1199%
06-10Free

Director

106,393 0.2407%
06-10Free

Director

106,393 0.2407%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%-6.37%-49.39%-58.57% 41.91M
+2.03%+3.19%+21.31%-19.42% 63.09B
+0.74%+3.52%+53.14%+219.37% 55.61B
-3.10%+34.30%+34.30%+34.30% 41.64B
-2.36%+6.28%-51.83%-59.27% 38.98B
+5.51%+6.95%+68.29%-24.14% 29.82B
+12.85%+13.01%+143.52%-44.30% 23.71B
+5.20%+9.24%+59.92%+79.92% 21.48B
-1.25%-1.31%-8.80%+146.80% 16.87B
-0.81%+4.81%+67.70%+124.13% 16.74B
Average +1.87%+1.91%+33.82%+39.88% 30.8B
Weighted average by Cap. +1.59%+3.29%+37.07%+47.37%

Financials

2026 *2027 *
Net sales 12M 10.52M 9.7M 9.08M 17.03M 1.13B 17.38M 117M 45.11M 559M 45.06M 44.08M 1.94B 13.1M 11.49M 10.59M 9.91M 18.59M 1.24B 18.97M 127M 49.24M 611M 49.19M 48.12M 2.12B
Net income -25.9M -22.71M -20.93M -19.6M -36.75M -2.44B -37.51M -252M -97.35M -1.21B -97.25M -95.13M -4.19B -22.4M -19.64M -18.1M -16.95M -31.78M -2.11B -32.44M -218M -84.2M -1.04B -84.11M -82.28M -3.62B
Net Debt - -
Logo Elutia Inc.
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Employees
26
Date Price Change Volume
26-06-26 US$0.9362 -1.26% 26,145
26-06-25 US$0.9481 -3.36% 66,927
26-06-24 US$0.9811 -4.75% 95,591
26-06-23 US$1.030 +3.00% 76,451
26-06-22 US$1.000 -5.66% 74,752
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9481USD
Average target price
5.000USD
Spread / Average Target
+427.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELUT Stock